Healthcare / Diagnostics & ResearchNasdaqCM
$2.23
-0.33 (-12.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-17.6M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$51M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-2526.6%
↓Gross Margin
72.6%
↑Debt/Equity
4.01
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.5%
FCF CAGR
—
FCF margin
-2240.0%
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $537080.0 · net income $-16.2M · FCF $-12.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $537080.00 | $537080.00 | $893991.00 | $895479.00 | $529877.00 |
| Net Income | $-16.2M | $-16.2M | $-21.6M | $-26.3M | $-26.4M |
| EBITDA | $-15.2M | $-15.2M | $-20.0M | $-24.9M | $-25.7M |
| EPS | -2.70 | -2.70 | -21.91 | -64.76 | -74.55 |
| Gross Margin | 72.6% | 72.6% | 64.3% | 56.9% | 34.4% |
| Operating Margin | -2414.0% | -2414.0% | -2063.8% | -2975.5% | -4990.6% |
| Net Margin | -3018.3% | -3018.3% | -2416.0% | -2936.5% | -4979.9% |
| Balance Sheet | |||||
| Debt/Equity | 4.01 | 4.01 | 0.58 | 2.28 | 0.23 |
| Current Ratio | 2.11 | 2.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.0M | $-12.0M | $-17.6M | $-23.8M | $-15.4M |
| Returns | |||||
| ROE | -2526.6% | -2526.6% | -360.1% | -809.3% | -187.2% |
| Valuation | |||||
| P/B | 20.84 | 20.84 | 0.72 | 0.14 | 0.16 |
| Growth & Yield | |||||
| Revenue Growth | -39.9% | -39.9% | -0.2% | 69.0% | — |
| EPS Growth | 87.7% | 87.7% | 66.2% | 13.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+10.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-21.91 → -2.70
Residual
+10.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.